Replies to post #1399 on ImmunityBio Inc (IBRX)

[mick]

ImmunityBio, NantKwest Announce First Patient Dosed in Phase 1 Clinical Trial of Second-Generation COVID-19 Vaccine Candidate... Business Wire - 10/21/2020 5:06:00 PM
FDA Authorizes Phase 1 Trial of ImmunityBio’s Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Bo... Business Wire - 10/15/2020 6:00:00 AM
NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial; Opens Study to Patients Who Have Failed All ... Business Wire - 10/6/2020 4:05:00 PM